Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00642499 · ClinicalTrials.gov registry record · Phase 2

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

A Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, sponsored by Solvay Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
103
Enrollment target
20
Study locations

NCT00642499 is a Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 103 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00642499, a Phase 2 study of HIV Infections and Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, has completed, sponsored by Solvay Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
103 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients

Interventions

  • DRUG Placebo
  • DRUG Dronabinol

Study Locations (20)

Florida

  • Site 907 - Altamonte Springs
  • Site 948 - Miami
  • Site 951 - Miami
  • Site 953 - Miami
  • Site 959 - Miami
  • Site 954 - North Palm Beach
  • Site 957 - Pensacola
  • Site 923 - Port Saint Lucie
  • Site 929 - Sarasota
  • Site 952 - Tallahassee
  • Site 931 - Tampa

California

  • Site 911 - Bakersfield
  • Site 919 - Fresno
  • Site 924 - Los Angeles
  • Site 932 - Los Angeles
  • Site 926 - Palm Springs
  • Site 946 - Pasadena
  • Site 913 - Tarzana

Georgia

  • Site 908 - Decatur

Idaho

  • Site 905 - Boise

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2003-08
Est. Completion 2005-04
Phase Phase 2

Sponsor

Solvay Pharmaceuticals

35 total trials

What the Registry Record Tells You About NCT00642499

The ClinicalTrials.gov registry entry for NCT00642499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (77% lower). The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00642499 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT00642499 about?

NCT00642499 is a clinical study titled "Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting". The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients

What is the current status of trial NCT00642499?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2003-08. Estimated completion is 2005-04.

What conditions does trial NCT00642499 study?

This clinical trial studies the following conditions: HIV Infections, Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting.

What interventions are being tested in trial NCT00642499?

The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).

Who is sponsoring clinical trial NCT00642499?

This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00642499 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.